NBSE News and Press, NeuBase Therapeutics Inc. From 09/14/21

PITTSBURGH, Sept. 14, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic med...

David Einhorn's 13F stock portfolio value increased from $1.44B to $1.59B this quarter. Greenlight increased Teck Resources, GoPro, and The ODP Corp while reducing APi Group, CNX Resources, and Katapult Holdings during the quarter. They also dropped ADT Inc. and Alight Inc. The la...

PITTSBURGH, Sept. 01, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicin...

Further demonstrated broad potential of novel genetic medicine platform with in vivo data in three diseases driven by different genetic mechanisms of disease Presented preclinical data showing compounds enabled with NeuBase’s proprietary delivery technology are well tol...

Glenview Capital Management’s 13F portfolio value increased from $4.36B to $5.90B this quarter. The number of positions increased from 54 to 63. They increased AmerisourceBergen, Facebook, Alphabet, and Baxter International while reducing Laboratory Corp. and dropping Expedia G...

Data presented today at NeuBase’s R&D Day show functional rescue of myotonic dystrophy type 1 (DM1) phenotype in vivo after subcutaneous dosing; positions program to enter the clinic in CY 2022 Company also presented data demonstrating selective reduction of mutan...

David Einhorn's 13F stock portfolio value decreased from $1.66B to $1.44B this quarter. Greenlight increased Danimer Scientific and Concentrix while reducing AerCap Holdings, fuboTV, and Resideo Technologies during the quarter. The largest three positions are at ~45% of the portfo...

Company to present new preclinical data in myotonic dystrophy type 1 to support a path to enter the clinic in 2022, as well as provide updates on the Huntington’s disease program and unveil a new oncology program targeting high-value genetic driver mutations KOLs in pepti...

PITTSBURGH, May 25, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of precision genetic medicines, today announced the appointment of Kia Motesharei, Ph.D., as Chi...

PITTSBURGH, May 20, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of precision genetic medicines, today announced the appointment of Sandra Rojas-Caro, M.D., as C...